

PTO/SB/08-03

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/06/2009. GPO 2007-093

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1-1000

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

Substitute for form 1-473-GPO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/679,081
		Filing Date	10/3/2003
		First Named Inventor	Hans-Michael Dosch
		Art Unit	1632
		Examiner Name	Louis D. Lieft
		Attorney Docket Number	2560.001
Sheet	1	of	5

U. S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)			
LDL	WO01/14877 A2		03/01/2001	Orgentec Diagnostika GMBH	
LDL	WO02/16414 A2		02/28/2002	Micromet AG	

Examiner Signature  Date Considered 01-06-05

<sup>1</sup>EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/679,081
				Filing Date	10/3/2003
				First Named Inventor	Hans-Michael Dosch
				Art Unit	1632
				Examiner Name	Licto
Sheet	2	of	5	Attorney Docket Number	2560.001

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
UPL		S. WINER et al, "ICA69null nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide", Journal of Immunology, 168(1):475-482 (January, 2002)			
		S. MARTIN et al, "Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis", Diabetologia, 38(3):351-355 (March, 1995)			
		S. WINER et al, "ICA69null NOD congenic mice are protected from sialitis and cyclophosphamide-accelerated diabetes", Diabetes, 50(Supp 2):A503 (June, 2001) Abstract XP008028882, 2114-PO			
		K. YANAGI et al, "Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NDO mouse model of Sjogren's syndrome", Eur. J. Immunol., 28(10):3336-3345 (October, 1998)			
		S. WINER et al, "Primary Sjogren's syndrome and deficiency of ICA69", The Lancet, 360(9339):1063-1069 (October, 2002)			
		R. FOX et al, "Update in Sjogren syndrome", Current Opinion in Rheumatology, 12:391-398 (2000)			
		J. JAMES et al, "Role of viruses in systemic lupus erythematosus and Sjogren syndrome", Current Opinion in Rheumatology, 13:370-376 (2001)			
		R. FOX et al, "Current issues in the diagnosis and treatment of Sjogren's syndrome", Current Opinion in Rheumatology, 11(5):364-371 (September, 1999)			
		J. HARLEY et al, "Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogren's syndrome", Arthritis and Rheumatism, 29(2):196-206 (February, 1986)			
✓		O. BILLAUT-MULOT et al, "SS-56, a novel cellular target of autoantibody responses in Sjogren syndrome and systemic lupus erythematosus", The Journal of Clinical Investigation, 108(6):861-869 (September, 2001)			

Examiner Signature		Date Considered	5.26.05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449/PTO					
				<b>Application Number</b>	10/679,081
				<b>Filing Date</b>	10/3/2003
				<b>First Named Inventor</b>	Hans-Michael Dosch
				<b>Art Unit</b>	1632
				<b>Examiner Name</b>	Licto
Sheet	3	of	5	<b>Attorney Docket Number</b>	2560.001

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
UDL		N. HANEJI et al, "Identification of alpha-Fodrin as a candidate autoantigen in primary Sjogren's syndrome", Science, 276:604-607 (April, 1997)			
		M. KUWANA et al, "Autoantibodies to the amino-terminal fragment of beta-Fodrin expressed in glandular epithelial cells in patients with Sjogren's syndrome", The Journal of Immunology, 167:5449-5456 (2001)			
		C. ROBINSON et al, "Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome", Proc. Natl. Acad. Sci. USA, 95:7538-7543 (June, 1998)			
		M. HUMPHREYS-BEHER et al, "Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjogren's syndrome". Adv. Exp. Med. Biol., 350:631-636 (1994)			
		R. HOFFMAN et al, "Sjogren's syndrome in MRL/l and MRL/n mice", Arthritis and Rheumatism, 27(2):157-165 (February, 1984)			
		N. HANEJI et al, "A new animal model for primary Sjogren's syndrome in NFS/lid mutant mice", The Journal of Immunology, 153:2769-2777 (1994)			
		J. BRAYER et al, "Sjogren's syndrome: immunological response underlying the disease", Arch. Immunol. Ther. Exp., 49:353-360 (2001)			
		C. ROBINSON et al, "A novel NOD-derived murine model of primary Sjogren's syndrome", Arthritis & Rheumatism, 41(1):150-156 (January, 1998)			
		W. KARGES et al, "Loss of self-tolerance to ICA69 in nonobese diabetic mice", Diabetes, 46:1548-1556 (October, 1997)			
X		H.-MICHAEL DOSCH et al, "Persistent T cell energy in human type 1 diabetes", The Journal of Immunology, 162:6933-6940 (1999)			

Examiner Signature		Date Considered	S 26. 85
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete If Known**

Substitute for form 1449/PTO				
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				
(Use as many sheets as necessary)				
Sheet	4	of	5	Attorney Docket Number
2560.001				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LNC		M. PILON et al, "The diabetes autoantigen ICA69 and its <i>Caenorhabditis elegans</i> homologue, ric-19, are conserved regulators of neuroendocrine secretion", Molecular Biology of the Cell, 11:3277-3288 (October, 2000)	
		S. WINER et al, "ICA69 null nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide", The Journal of Immunology, 168:475-482 (2002)	
		W. KARGES et al, "Gene expression of islet cell antigen p69 in human, mouse, and rat", Diabetes, 45:513-521 (April, 1996)	
		S. WINER et al, "Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis", The Journal of Immunology, 166:2831-2841 (2001)	
		D. SERREZE et al, "B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.Igmu null mice", J. Exp. Med., 184:2049-2053 (November, 1996)	
		S. WINER et al, "Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes", The Journal of Immunology, 165:4086-4094 (2000)	
		H.-M. DOSCH et al, "Measurement of T-cell autoreactivity in autoimmune diabetes", Diabetologia, 43:386-387 (2000)	
		R. HUNGER et al, "Male gonadal environment paradoxically promotes dacryoadenitis in nonobese diabetic mice", J. Clin. Invest., 101(6):1300-1309 (March, 1998)	
		W. CHEN et al, "Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes", The Journal of Immunology, 167:4926-4935 (2001)	
AK		C. LAFITTE et al, "Neurological complications of primary Sjogren's syndrome", Journal of Neurology, 248(7):577-584 (July, 2001)	

Examiner Signature		Date Considered	6/6/05
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449/PTO				
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				
Sheet	5	of	5	Attorney Docket Number
				2560.001

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LDC		A. ANDONOPoulos et al, "The spectrum of neurological involvement in Sjogren's syndrome", The British Journal of Rheumatology, 29:21-23 (1990)	
		K. MALINOW et al, "Subacute sensory neuropathy secondary to dorsal root ganglionitis in primary Sjogren's syndrome", Ann. Neurol., 20:535-537 (1986)	
		T. CHUSED et al, "Sjogren's syndrome association with HLA-Dw3", N. Engl. J. Med., 296(16):895-897 (April, 1977)	
		H. FOSTER et al, "Linkage studies of HLA and primary Sjogren's syndrome in multicase families", Arthritis and Rheumatism, 36(4):473-484 (April, 1993)	
		E. GOILLOT et al, "Sialadenitis in nonobese diabetic mice: transfer into syngeneic healthy neonates by splenic T lymphocytes", Clin. Immunol. Immunopathol., 59:462-473 (1991)	
		K. YANAGI et al, "Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjogren's syndrome", Eur. J. Immunol., 28:3336-3345 (1998)	
		R. MASAGO et al, "Elevated Proapoptotic Bax and Caspase 3 activation in the NOD.scid model of Sjogren's syndrome", Arthritis & Rheumatism, 44(3):693-702 (March, 2001)	
		C. ROBINSON et al, "Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice", Clin. Immunol. Immunopathol., 79(1):50-59 (April, 1996)	
↓		J. GROOM et al, "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome", The Journal of Clinical Investigation, 109(1):59-68 (January, 2002)	

Examiner Signature	<i>MD LDC</i>	Date Considered	606-05
--------------------	---------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.